Viking Therapeutics tumbles 8%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Viking Therapeutics (VKTX.US) tumbled more than 8% during regular trading to $26.86.

The stock is down 23.65% year to date and sits 37.68% below its 52-week high of US$43.10.

The Nasdaq Composite is down 2.67% over the past five sessions and up 5.75% year to date.

The company reported zero revenue for the third quarter of 2026, with a loss per share of $1.55, wider than the IBES consensus of $1.07. Net loss widened to $183.2 million, while operating expenses surged nearly 90% year-over-year to $187.1 million, driven primarily by the expansion of Phase 3 clinical trials for its obesity drug VK2735.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Recommended Readings